Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Adaptimmune CEO James Noble © Adaptimmune

Adaptimmune downgrades trial design after FDA clinical hold

Oxford-based immuno-oncology play Adaptimmune has been obliged by the FDA to alter the trial design of a Phase I/II study in patients with MRCLS. A partial clinical hold was lifted now.

Read more
Studies on twins reveal: the natural intestinal flora can trigger Multiples Sclerosis (left). T-cells (blue) play a central role. © MPI of Biochemistry/ Menzfeld

Multiple sclerosis diagnosis in early stage

Belgian and German researchers have presented a new imaging tool that can track immune cells invading the brain in the initial stages of multiple sclerosis (MS). 

Read more
OPIS

COMPASS Innovative web-platform developed by OPIS to manage Compassionate Use Programmes

Compassionate use is a treatment option that allows the use of an unauthorised medicine.

Read more
PromoCell GmbH

Cell Proliferation Kits III

PromoKine’s new Cell Proliferation Assays are fast and sensitive and EdU-based.

Read more
© EBD Group via Twitter

BIO Europe with new record numbers

Despite declining numbers of IPOs, financing rounds and licensing deals, the European biotech sector presented itself optimistic and self-confident during BIO-Europe in Cologne. The three-days partnering event again see a record number of participants. 

Read more